Company Overview and News

 
UPDATE 2-European stock index scores best winning streak in two decades

10h reuters
LONDON (Reuters) - Easing fears of a trade war further lifted European shares on Friday, with trade-sensitive sectors like miners .SXPP and autos .SXAP leading the advance.
JSTLF BNPZY DB BNPQY JE BNPQF JSTTY

 
The Fed: With its last easy decision, Fed will try to avoid adding fuel to the fire

10h marketwatch
Ask any Wall Street economist if the Federal Reserve will raise interest rates at its September meeting and the answer is “of course.”
BNPZY DB BNPQY BNPQF

 
BNP Paribas Cardif to sell stake in SBI Life Insurance

2018-09-21 livemint
Mumbai: French insurer BNP Paribas Cardif has appointed three investment banks to scout for buyers for a portion of its stake in SBI Life Insurance Co. Ltd that is worth at least $500 million, said two people aware of the development. BNP Paribas Cardif formed the life insurance joint venture with state-run lender State Bank of India (SBI) in 2001. SBI currently owns 62.1% in the company while BNP Paribas Cardif holds 22%.
BNPZY BNPQY BNPQF SBAZ

2
Aramco Is Not Alone as Saudi Arabia's Privatization Push Slows

2018-09-20 rigzone
(Bloomberg) -- Aramco may have grabbed the biggest headlines, but the oil giant’s delayed initial public offering is just the latest sign of Saudi Arabia’s slowing privatization push.
BNPZY BNPQY 8306 MUFG BNPQF MBFJF MTU

4
REFILE-MOVES- BlackRock names Butler to lead US CLO business

2018-09-20 reuters
NEW YORK, Sept 20 (LPC) - BlackRock has named Owen Butler to lead the firm’s US Collateralized Loan Obligation (CLO) business within the credit group.
WFC WFCNP BNPQY BNPQF BNPZY

15
Akzo Nobel loans break for trading

2018-09-20 reuters
NEW YORK, Sept 20 (LPC) - The US$6.44bn in term loans backing Carlyle Group and Singaporean wealth fund GIC’s acquisition of Akzo Nobel’s chemicals business allocated and broke for trading on Thursday.
BGX STAN DB BNPQY AKZA CG BX BGLF BNPQF BGB BNPZY STAB 580001 STAC SCBFF STAN 2888 MS

4
MOVES- BlackRock names Butler to lead US CLO business

2018-09-20 reuters
NEW YORK, Sept 20 (LPC) - BlackRock has named Owen Butler to lead the firm’s US Collateralized Loan Obligation (CLO) business.
WFC WFCNP BNPQY BNPQF BNPZY

 
Elanco Explodes Into the Market in IPO

2018-09-20 247wallst
Elanco Animal Health Inc. (NYSE: ELAN) made a strong entrance to the market on Thursday. Shares went out at $32.25, well above the high end of the expected price range of $20 to $23. The company offered 62.9 million shares, with an overallotment option for an additional 9.435 million shares.
BNPZY DB BNPQY LLY BNPQF MS

 
Oil steady as Trump tweet slows surge upwards

2018-09-20 malaymail
LONDON, Sept 20 — Oil prices steadied today after US President Donald Trump called on Opec to “get prices down now!”, slowing an upward surge that has pushed the market towards four-year highs.
BNPZY BNPQY BNPQF

 
Mario Draghi: Turkey's Helper?

2018-09-20 seekingalpha
This is Part 2 of a two-part series on Turkey's crisis and the implications for Europe. In Part One, Getting More Defensive in European Portfolios, we identified the WisdomTree Germany Hedged Equity Fund (NASDAQ:DXGE) and the WisdomTree Europe Hedged Equity Fund (NYSEARCA:HEDJ) as two ETFs that may help minimize European financial sector risk, specific bank risk from the four institutions that hold Turkish debt in size, and currency risk.
DFE BNPZY BNPQY BNPQF DXGE EUSC

 
OPEC's Decade of Turmoil Leaves Cartel Seeking a New Way Forward

2018-09-20 rigzone
(Bloomberg) -- A global recession, both $140 and $30 oil, the U.S. shale revolution, a market-share war, and output cuts. OPEC’s 60-year history has rarely confronted a more challenging period than the past decade.
BNPZY BNPQY BNPQF

 
Energy, Banking Majors Launch Blockchain Oil Trading Platform

2018-09-20 oilprice
Tsvetana is a writer for the U.S.-based Divergente LLC consulting firm with over a decade of experience writing for news outlets such as iNVEZZ and…
BNPZY SCGLF BNPQY SCGLY GLE BNPQF

 
Danske Bank's mea culpa over alleged money laundering isn't the end. There are plot twists ahead

2018-09-19 cnbc
The popularity of Scandi noir rests on the contrast between the banal surface of Nordic societies and the nefarious activities underneath. An internal report into potential money laundering through Denmark's largest bank by assets – accompanied by the immediate resignation of appropriately named chief executive Thomas Borgen – has provided the latest must-watch installment. Danske Bank's problem is that further unpleasant plot twists lie ahead.
BNPZY DB BNPQY BNPQF

 
Banks, traders launch first commodities blockchain platform

2018-09-19 theedgemarkets
LONDON (Sept 19): Global banks and trading firms are launching the first blockchain-based platform for financing the trading of commodities from oil to wheat, they said in a joint statement on Wednesday.
BNPZY SCGLF BNPQY SCGLY GLE BNPQF

 
Oil Near Week's High as Supply Data Tempers Saudi View on Prices

2018-09-19 rigzone
(Bloomberg) -- Brent oil held near the highest level in a week as investors weighed a potential gain in U.S. crude stockpiles against Saudi Arabia’s comfort with prices rising above $80 a barrel.
BNPZY BNPQY BNPQF

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: F1058Q238